A 12-month, multi-center, open-label study to investigate the safety of pegpleranib (1.5 mg) in combination with anti-VEGF agents, ranibizumab (0.5 mg) or aflibercept (2 mg), in Japanese patients with neovascular age-related macular degeneration
Research Grant
Administered By
Ophthalmology
Awarded By
Novartis Pharma AG
Start Date
October 1, 2016
End Date
December 14, 2016
Administered By
Ophthalmology
Awarded By
Novartis Pharma AG
Start Date
October 1, 2016
End Date
December 14, 2016